

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

Francesco Marchesi,^{1*} Jon Salmanton-García,^{2,3*} Ziad Emarah,⁴ Klára Piukovics,⁵ Marcio Nucci,⁶ Alberto López-García,⁷ Zdeněk Ráčil,⁸ Francesca Farina,⁹ Marina Popova,¹⁰ Sofia Zompi,¹¹ Ernesta Audisio,¹¹ Marie-Pierre Ledoux,¹² Luisa Verga,^{13,14} Barbora Weinbergerová,¹⁵ Tomas Szotkovski,¹⁶ Maria Gomes Da Silva,¹⁷ Nicola Fracchiolla,¹⁸ Nick De Jonge,¹⁹ Graham Collins,²⁰ Monia Marchetti,²¹ Gabriele Magliano,²² Carolina García-Vidal,²³ Monika M. Biernat,²⁴ Jaap Van Doesum,²⁵ Marina Machado,²⁶ Fatih Demirkan,²⁷ Murtadha Al-Khabori,²⁸ Pavel Žák,²⁹ Benjamín Víšek,²⁹ Igor Stoma,³⁰ Gustavo-Adolfo Méndez,³¹ Johan Maertens,³² Nina Khanna,³³ Ildefonso Espigado,³⁴ Giulia Dragonetti,³⁵ Luana Fianchi,³⁵ Maria Ilaria Del Principe,³⁶ Alba Cabirta,^{37,38} Irati Ormazabal-Vélez,³⁹ Ozren Jaksic,⁴⁰ Caterina Buquicchio,⁴¹ Valentina Bonuomo,⁴² Josip Batinić,^{43,44,45} Ali S. Omrani,⁴⁶ Sylvain Lamure,⁴⁷ Olimpia Finizio,⁴⁸ Noemí Fernández,⁴⁹ Iker Falces-Romero,⁵⁰ Ola Blennow,⁵¹ Rui Bergantim,⁵² Natasha Ali,⁵³ Sein Win,⁵⁴ Jens Van Praet,⁵⁵ Maria Chiara Tisi,⁵⁶ Ayten Shirinova,⁵⁷ Martin Schönlein,⁵⁸ Juergen Prattes,⁵⁹ Monica Piedimonte,⁶⁰ Verena Petzer,⁶¹ Milan Navrátil,⁶² Austin Kulasekararaj,⁶³ Pavel Jindra,⁶⁴ Jiří Sramek,^{65,66} Andreas Glenthøj,⁶⁷ Rita Fazzi,⁶⁸ Cristina De Ramón-Sánchez,^{69,70} Chiara Cattaneo,⁷¹ Maria Calbacho,⁷² Nathan C. Bahr,⁷³ Shaimaa El-Ashwah,⁴ Raul Cordoba,⁷ Michaela Hanakova,⁸ Giovanni Paolo Maria Zambrotta,¹³ Giovanni Zambrotta,¹⁴ Mariarita Sciumè,¹⁸ Stephen Booth,²⁰ Raquel Nunes Rodrigues,¹⁷ Maria Vittoria Sacchi,²¹ Nicole García-Poutón,²³ Juan-Alberto Martín-González,⁷⁴ Sofya Khostelidi,⁷⁵ Stefanie Gräfe,^{76,2,3} Laman Rahimli,^{2,3} Emanuele Ammatuna,²⁵ Alessandro Busca,¹¹ Paolo Corradini,⁷⁷ Martin Hoenigl,^{78,79,80} Nikolai Klimko,⁷⁵ Philipp Koehler,^{2,3} Antonio Pagliuca,⁸¹ Francesco Passamonti,⁸² Oliver A. Cornely,^{2,3,83,84#} and Livio Pagano^{35,85#}

Correspondence: J. SALMANTON-GARCÍA
jon.salmanton-garcia@uk-koeln.de

Received: February 11, 2022.

Accepted: May 5, 2022.

Prepublished: May 12, 2022.

<https://doi.org/10.3324/haematol.2022.280847>

©2023 Ferrata Storti Foundation

Published under a CC BY-NC license



¹Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy; ²University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; ³University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany; ⁴Oncology Center, Mansoura University, Mansoura, Egypt; ⁵Department of Internal Medicine, South Division Faculty of Medicine University of Szeged, Szeged, Hungary; ⁶Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; ⁷Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain; ⁸Institute of Hematology and Blood Transfusion, Prague, Czech Republic; ⁹IRCCS Ospedale San Raffaele, Milan, Italy; ¹⁰RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia; ¹¹Stem Cell Transplant Center, AOU Citta' della Salute e della Scienza, Turin, Italy; ¹²Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France; ¹³Azienda Ospedaliera San Gerardo - Monza, Monza, Italy; ¹⁴Università Milano-Bicocca, Milan, Italy; ¹⁵Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic; ¹⁶University Hospital Olomouc, Olomouc, Czech Republic; ¹⁷Portuguese Institute of Oncology, Lisbon, Portugal; ¹⁸Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹⁹Amsterdam UMC, location VUmc, Amsterdam, the Netherlands; ²⁰Oxford University Hospitals, Oxford, UK; ²¹Azienda Ospedaliera Nazionale "SS. Antonio e Biagio e Cesare Arrigo", Alessandria, Italy; ²²ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; ²³Department of Infectious Diseases, Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain; ²⁴Department of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; ²⁵University Medical Center Groningen, Groningen, the Netherlands; ²⁶Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ²⁷Division of Hematology, Dokuz Eylul University, Izmir, Turkey; ²⁸Sultan Qaboos University Hospital, Muscat, Oman; ²⁹University Hospital Hradec Králové, Hradec Králové, Czech Republic; ³⁰Gomel State Medical University, Gomel, Belarus; ³¹Hospital Escuela de Agudos Dr. Ramón Madariaga, Posadas, Argentina; ³²Department of Microbiology, Immunology, and Transplantation, KU Leuven and Department of Hematology, UZ Leuven, Leuven, Belgium; ³³Division of Infectious Diseases and Hospital Epidemiology, and Department of Clinical Research, University and University Hospital of Basel, Basel, Switzerland; ³⁴Department of Hematology, University Hospital Virgen Macarena - University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla, Seville, Spain; ³⁵Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy; ³⁶Hematology Unit, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy; ³⁷Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain; ³⁸Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ³⁹Complejo Hospitalario de Navarra, Iruña-Pamplona, Spain; ⁴⁰University Hospital Dubrava, Zagreb, Croatia; ⁴¹Ematologia con Trapianto, Ospedale Dimiccoli Barletta, Barletta, Italy; ⁴²Department of Medicine, Section of Hematology, University of Verona, Verona, Italy; ⁴³Croatian Cooperative Group for Hematological Diseases (CROHEM), Zagreb, Croatia; ⁴⁴Faculty of Medicine University of Zagreb, Zagreb, Croatia; ⁴⁵University Hospital Centre Zagreb, Zagreb, Croatia; ⁴⁶Hamad Medical Corporation, Division of Infectious Diseases, Doha, Qatar; ⁴⁷Département d'Hématologie Clinique, CHU de Montpellier, UMR-CNRS 5535, Université de Montpellier, Montpellier, France; ⁴⁸UOC Hematology, AORN Cardarelli, Naples, Italy; ⁴⁹Hospital Universitario Marqués de Valdecilla, Santander, Spain; ⁵⁰La Paz University Hospital, Madrid, Spain; ⁵¹Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; ⁵²Centro Hospitalar e Universitário São João, Porto, Portugal; ⁵³Aga Khan University Hospital, Karachi, Pakistan;


ARTICLE - Acute Myeloid Leukemia

⁵⁴Department of Clinical Hematology, Yangon General Hospital, University of Medicine, Yangon, Myanmar; ⁵⁵Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium; ⁵⁶Ospedale San Bortolo, Vicenza, Italy; ⁵⁷Azerbaijan Scientific Research Hematology and Transfusiology Institute, Baku, Azerbaijan; ⁵⁸Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁵⁹Medical University of Graz, Department for Infectious Diseases, Graz, Austria; ⁶⁰AOU Sant'Andrea, Rome, Italy; ⁶¹Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria; ⁶²Head of the ICU and Transplant Unit, Department of Hematooncology, University Hospital of Ostrava, Ostrava-Poruba, Czech Republic; ⁶³King's College Hospital, London, UK; ⁶⁴University Hospital Pilsen, Pilsen, Czech Republic; ⁶⁵Department of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic; ⁶⁶Department of Histology and Embryology, Faculty of Medicine, Pilsen, Czech Republic; ⁶⁷Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; ⁶⁸AOUP - Azienda Ospedaliera Università Pisana - Cisanello, Pisa, Italy; ⁶⁹Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain; ⁷⁰IBSAL, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain; ⁷¹Hematology Unit, ASST-Spedali Civili, Brescia, Italy; ⁷²Hospital Universitario 12 de Octubre, Madrid, Spain; ⁷³University of Kansas Medical Center, Kansas City, USA; ⁷⁴Hospital Universitario Virgen del Rocío, Seville, Spain; ⁷⁵North-Western State Medical University named after Iliá Ilich Méchnikov, Saint-Petersburg, Russia; ⁷⁶Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; ⁷⁷University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁷⁸Clinical and Translational Fungal-Working Group, University of California San Diego, La Jolla, CA, USA; ⁷⁹Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA; ⁸⁰Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria; ⁸¹Department of Haematological Medicine, Kings College Hospital NHS Foundation Trust, London, UK; ⁸²Department of Medicine and Surgery, University of Insubria and ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy; ⁸³German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany; ⁸⁴University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany and ⁸⁵Hematology Unit, Università Cattolica del Sacro Cuore, Rome, Italy

**FM and JSG contributed equally as co-first authors.*



#OAC and LP contributed equally as co-senior authors.

Figure S1



Number of patients at risk


<i>Tx not delayed, not discontinued</i>	14	9	7	3	2	0	0	0
<i>Tx delayed, not discontinued</i>	10	8	8	7	3	1	1	0
<i>Tx discontinued</i>	32	6	3	2	0	0	0	0



Number of patients at risk

<i>January-August 2020</i>	127	58	49	38	28	20	14	0
<i>September 2020-February 2021</i>	238	130	95	81	19	0	0	0
<i>March-September 2021</i>	21	8	3	0	0	0	0	0



Figure S3



Number of patients at risk

<i>Tx not delayed, not discontinued</i>	11	8	6	4	1	0	0	0
<i>Tx delayed, not discontinued</i>	19	18	14	11	4	2	1	0
<i>Tx discontinued</i>	17	10	6	5	2	2	1	0


Figure S4



Number of patients at risk

<i>Tx not delayed, not discontinued</i>	1	1	1	1	0	0	0	0
<i>Tx delayed, not discontinued</i>	7	6	3	2	1	1	1	0
<i>Tx discontinued</i>	14	1	1	1	1	0	0	0

Figure S5



Number of patients at risk

	0	100	200	300	400	500	600	700
<i>Tx not delayed, not discontinued</i>	14	10	5	3	0	0	0	0
<i>Tx delayed, not discontinued</i>	36	32	23	18	6	3	2	0
<i>Tx discontinued</i>	21	10	7	6	3	2	1	0

Supplementary figures' legend

Figure S1. Survival probability by modification of initial chemotherapeutic program due to COVID-19 in 79 with concomitant AML and COVID-19 diagnosis.

Figure S2. Survival probability by observation time (Jan-2020 to Aug-2020 vs Sept-2020 to Feb-2021 vs Mar-2021 to Sept-2021).

Figure S3. Survival probability by modification of initial chemotherapeutic program due to COVID-19 diagnosis in patients receiving consolidation treatment.

Figure S4. Survival probability by modification of initial chemotherapeutic program due to COVID-19 diagnosis in relapsed/refractory patients receiving reinduction treatment.

Figure S5. Survival probability by modification of initial chemotherapeutic program due to COVID-19 diagnosis in CR patients.